Allogene Therapeutics (ALLO) Stock Surges 41% On Positive CAR T Trial Data

TLDR

• Allogene’s ALPHA3 trial showed 58.3% MRD clearance in the cema-cel arm vs 16.7% under observation
• No cytokine release syndrome or neurotoxicity was observed in treated patients
• Baird raised its price target on ALLO from $7.00 to $9.00, keeping an Outperform rating
• Baird increased its probability of success estimate for the program to 70%
• ALLO stock jumped to $3.87 from a previous close of $2.91, up roughly 99% year-to-date

Allogene Therapeutics shares surged over 41% on April 13, 2026, after the company released positive interim data from its pivotal Phase 2 ALPHA3 trial evaluating cemacabtagene ansegedleucel (cema-cel) in high-risk large B-cell lymphoma patients.

Allogene Therapeutics, Inc., ALLO

The data was presented as part of an interim futility analysis. Among the first 24 randomized patients, 58.3% in the cema-cel arm achieved minimal residual disease (MRD) negativity. In the observation arm, only 16.7% reached that outcome — a difference of 41.6 percentage points.

The trial uses Natera’s investigational CLARITY MRD assay to identify high-risk patients before clinical relapse occurs. Cema-cel is being evaluated as a first-line consolidation therapy, which would place it earlier in the treatment sequence than most current CAR T approaches.

Safety Profile Draws Attention

The safety data may have been just as eye-catching as the efficacy numbers. None of the treated patients experienced cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome — two side effects commonly associated with CAR T therapies.

There were no treatment-related serious adverse events reported. That kind of profile is unusual in this space, and Baird flagged it as a differentiating factor when comparing cema-cel to second-line autologous CAR T therapies.

The outpatient-feasible nature of the approach, combined with the safety data, is part of what makes the program potentially distinct. Most CAR T treatments currently require inpatient administration and carry heavier toxicity burdens.

Baird raised its price target on ALLO from $7.00 to $9.00 following the data release, maintaining its Outperform rating. The firm lifted its probability of success estimate for the program to 70%.

What Comes Next

The ALPHA3 study is enrolling approximately 220 patients across more than 60 sites. Efficacy endpoints remain blinded at this stage, and the dataset is still small. The numbers will need to hold up as the trial matures.

Planned interim event-free survival analyses are expected in 2027, with primary results targeted for 2028. Positive outcomes could support a future biologics license application.

Other analysts are also paying attention. Jefferies recently initiated coverage on ALLO with a Buy rating and a $6.00 price target, while Citizens reiterated its Market Outperform rating with a $5.00 target.

ALLO traded at $3.87 on April 13, up from a prior close of $2.91. The stock is up roughly 99% year-to-date and is trading near its 52-week high. InvestingPro data notes the stock is currently trading above its estimated fair value, though the company holds more cash than debt on its balance sheet.

The post Allogene Therapeutics (ALLO) Stock Surges 41% On Positive CAR T Trial Data appeared first on CoinCentral.